Core Insights - Neusoft Corporation and Cerence AI have signed a Memorandum of Understanding to collaborate on large language model-based voice AI solutions for the automotive industry [1][2] - The partnership aims to enhance in-cabin user experiences by providing intelligent interaction solutions that meet rising user expectations for natural language communication [2][5] Company Overview - Neusoft Corporation is a leading information technology company founded in 1991, recognized as the first listed software company in China, with a focus on intelligent vehicle connectivity, healthcare, smart cities, and digital transformation [6] - Cerence Inc. is a global leader in AI-powered experiences for automotive and transportation, with over 525 million cars equipped with its technology, emphasizing voice, generative AI, and large language models [7] Collaboration Details - Neusoft will utilize its advanced intelligent cockpit software platform (NAGIC) to integrate Cerence AI's expertise in conversational AI and large language models, aiming for innovative applications in voice interaction [3][4] - The collaboration will leverage Neusoft's global product development network and Cerence AI's technological strengths to expand into global target markets [4] Future Outlook - Neusoft plans to continue its philosophy of open collaboration and shared ecosystem success, working with more technology partners to address market challenges in automotive intelligence and AI [5]

东软集团表示，面向未来，公司将继续秉持"开放融合、生态共赢"的理念，与更多顶尖技术伙伴在汽车 智能化、AI化趋势下深度协同，共同助力车企在市场中破局，为全球用户打造更安全、更具温度的智 能出行体验。 随着汽车技术向智能化、情感化不断演进，用户对座舱交互的期待进一步提升。人们不再满足于基础的 语音响应，更需要一个能真正理解自然语义、交流顺畅且具备情感共鸣的出行伙伴。东软集团与 Cerence AI的强强联合，正是瞄准这一行业趋势，希望让"听得懂、答得准、有温度"的交互体验成为智 能汽车"新标配"。 Cerence AI是全球领先的对话式AI用户体验解决方案提供商。此次合作，东软集团将以先进的NAGIC智 能座舱软件平台为核心载体，深度融合Cerence AI在语音技术、生成式AI以及大语言模型方面的先进技 术与专业经验，围绕高频出行场景，共同探索智能语音交互的创新应用。 依托东软集团广泛的全球产品研发与交付网络，以及Cerence AI的技术优势与品牌影响力，双方将携手 开拓全球目标市场。 "东软集团"微信公众号1月22日消息，近日，东软集团与Cerence AI正式签署合作谅解备忘录。双方宣 布，将围绕智能语 ...

人民财讯1月22日电，近日，东软集团（600718）与Cerence AI正式签署合作谅解备忘录。双方宣布， 将围绕智能语音、大语言模型等前沿领域开展深度合作。通过技术共创、生态融合，共同为全球汽车伙 伴打造预集成、场景化、高体验的智能交互解决方案。 ...

Group 1 - The article discusses the recent policy measures issued by Guangdong province aimed at promoting high-quality development in transportation through artificial intelligence [4][5] - The policy encourages enterprises to focus on core technology breakthroughs and innovation in areas such as end-to-end remote driving, intelligent decision-making, and precise prediction and control [4][5] - The initiative aims to create high-quality data sets, toolchains, and algorithm libraries to facilitate the application of large models in autonomous driving [4][5] Group 2 - The article lists various companies involved in the development of key technologies related to autonomous driving, including 威帝股份, 凯众股份, and 大华股份 [6] - It highlights the importance of advanced systems such as steer-by-wire systems, vehicle-mounted cameras, and heads-up displays (HUD) in the context of intelligent driving [6]

Core Viewpoint - Neusoft Corporation has announced a restriction on the exercise period of its stock option incentive plan for 2024, due to the preliminary accounting of financial data for 2025, emphasizing a cautious approach [1]. Group 1: Stock Option Plan Details - The first exercise period for the 2024 stock option incentive plan (option code: 1000000589) is from May 26, 2025, to March 6, 2026, and is currently in the exercise phase [1]. - The restriction on the exercise period will be from January 25, 2026, to January 29, 2026, during which all incentive recipients will be restricted from exercising their options [1]. - The company will apply to the Shanghai branch of China Securities Depository and Clearing Co., Ltd. for the necessary procedures regarding the restriction on exercising options [1].

一、公司股票期权已进入行权期的情况 证券代码：600718 证券简称：东软集团 公告编号：临 2026-003 东软集团股份有限公司 关于股票期权激励计划限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担相应的法律责任。 根据公司 2024 年股票期权激励计划，以及中国证券登记结算有限责任公司 上海分公司关于股票期权自主行权的相关规定，鉴于目前公司正在对 2025 年度 财务数据进行初步核算，从审慎性原则出发，现对公司 2024 年股票期权激励计 划的自主行权时间进行限制，具体情况如下： 公司 2024 年股票期权激励计划的第一个行权期（期权代码：1000000589） 为 2025 年 5 月 26 日-2026 年 3 月 6 日，目前处于行权阶段。 二、本次限制行权期为：2026 年 1 月 25 日至 2026 年 1 月 29 日，在此期间， 全部激励对象将限制行权。 三、公司将按照有关规定，及时向中国证券登记结算有限责任公司上海分公 司申请办理限制行权相关事宜。 特此公告。 东软集团股份有限公司董事会 ...

Core Insights - The Chinese government has officially launched the "Artificial Intelligence +" initiative, focusing on enhancing the healthcare sector through AI applications, aiming to improve the quality of life and healthcare services [2] - The healthcare industry is becoming a primary area for AI technology implementation, transitioning from optional to essential applications, with significant growth expected in the AI healthcare market [2][3] Industry Overview - The healthcare sector faces critical challenges such as uneven resource distribution, high physician workloads, and low research translation efficiency, creating ample opportunities for AI applications [3] - By 2025, the global AI application market is projected to reach $127 billion, with the healthcare sector accounting for 20% of this total [2] - The "AI + healthcare" market is expected to grow at a compound annual growth rate of over 29%, reaching $70 billion by 2032 [2] AI Applications in Healthcare - AI applications in healthcare have evolved through various stages, with clinical decision support systems (CDSS) being a key area of focus, addressing the knowledge gap between medical advancements and physician expertise [3][4] - The introduction of large language models has significantly improved the capabilities of CDSS, allowing for real-time updates and broader disease coverage, with accuracy rates surpassing 91% in some cases [5][11] - Medical imaging AI has matured, transitioning from basic disease screening to advanced multi-modal analysis, enhancing diagnostic precision and patient outcomes [6][7] Business Models and Commercialization - The commercialization of medical imaging AI is shifting from product sales to service-based models, driven by the integration of AI into healthcare workflows [7][10] - Companies like Ping An are leveraging AI to enhance patient services, streamline processes, and improve healthcare accessibility, with AI assisting in over 50% of family doctor tasks [8][11] - The AI healthcare market is facing challenges related to high development costs, long return on investment periods, and difficulties in monetization due to varying payment capabilities across healthcare institutions [21][22] Challenges and Future Outlook - Despite advancements, the integration of AI in healthcare faces hurdles such as data quality, regulatory issues, and the need for explainability in AI decision-making [16][19] - The lack of standardized, high-quality data across healthcare institutions hampers the training of AI models, necessitating improvements in data governance and sharing mechanisms [18][19] - The AI + healthcare sector is expected to enter a new phase of large-scale implementation by 2026, driven by collaborative efforts and continuous technological innovation [22]

Core Insights - The release of the "2025 Shenyang Talent Demand Directory" serves as a strategic guide for talent recruitment and industrial upgrading in Shenyang, reflecting the city's industrial pulse and future planning [2] Group 1: Talent Demand and Industry Focus - The Shenyang Human Resources and Social Security Bureau has aligned the directory with the needs of the modern industrial system, emphasizing targeted talent acquisition rather than a generalized approach [3] - Four key industrial clusters—biomedicine and medical equipment, high-end equipment, integrated circuits, and new-generation information technology—account for over 170 critical job vacancies, with 82 positions classified as "five-star critical" [3] - The directory highlights a significant demand for top-tier talent and key skills in core technology areas, particularly in integrated circuits and biomedicine [3] Group 2: Structural Changes and Economic Indicators - The directory reveals a structural change in Shenyang's industrial development, with a clear demand for high-level technical talent across various sectors, including aerospace and new materials [4] - In 2024, Shenyang's high-tech manufacturing value added is projected to grow by 17.6%, significantly outpacing the average growth of 4.5% in industrial value added [4] - The demand for high-level, skilled, and interdisciplinary talent is expected to surge, particularly in fields like artificial intelligence and precision manufacturing [4] Group 3: Practical Implications for Companies - The directory provides companies with a precise recruitment roadmap, allowing them to focus their hiring efforts effectively [5] - Companies like Shenyang Siasun Robot & Automation Co. have successfully utilized the directory to identify specific talent needs and adjust compensation packages accordingly, improving recruitment efficiency [5] - The directory's identification of critical roles, such as "biopharmaceutical process development," aids in guiding educational institutions to focus on training applicable talent [5] Group 4: Long-term Talent Development - The directory emphasizes the importance of a systematic approach to talent development, linking educational institutions with industry needs to create a sustainable talent supply [6] - By providing clear professional structure requirements and core competency standards, the directory serves as a crucial link for deepening industry-education integration [6] - The alignment of talent supply with industrial demand is essential for addressing structural talent shortages effectively [6] Group 5: Strategic Vision for Shenyang - The directory acts as a comprehensive tool for both talent acquisition and development, supporting Shenyang's ambition to become a national advanced manufacturing center [7] - The collaborative efforts of policy guidance, market demand, corporate practices, and individual career development are crucial for realizing Shenyang's strategic blueprint [7] - A new narrative of innovation-driven development is emerging in Shenyang, fueled by a robust talent foundation [7]

Group 1 - The core point of the article is that Neusoft Corporation has won a procurement project from the National Taxation Administration with a bid amount of 3.15 million yuan, announced on January 14, 2026 [1][2]. Group 2 - Neusoft Corporation (600718.SH) reported a revenue of 11.56 billion yuan for 2024, with a revenue growth rate of 9.64% [2]. - The net profit attributable to the parent company for 2024 was 63 million yuan, with a net profit growth rate of -14.70% [2]. - The return on equity (ROE) for the company was 0.66% in 2024 [2]. - For the first half of 2025, the company reported a revenue of 4.689 billion yuan, with a revenue growth rate of 9.08% [3]. - The net profit attributable to the parent company for the first half of 2025 was 56 million yuan, with a net profit growth rate of -42.75% [3]. - The company operates in the information technology industry, with main product types including ERP software, firewall software, software outsourcing services, and industry-specific software [3]. - The main business composition for 2024 included self-developed software, products, and services (including medical equipment and Xikang) at 83.94%, system integration at 14.37%, and property advertising at 1.69% [3].

Core Insights - Neusoft Group's "Tianyi" AI 2.0 has been recognized as one of the "Top 10 AI Agents in the Healthcare Industry" due to its deep penetration in medical scenarios, technological innovation, and successful implementation in over 100 medical institutions [1][2] - The evaluation was conducted by Frost & Sullivan in collaboration with the Tiger Research Institute, assessing nearly 300 AI agents based on originality, practical application, and industry impact [1] Company Overview - "Tianyi" AI 2.0 integrates AI, data, processes, and organization into a comprehensive medical intelligence solution, focusing on six core scenarios: smart healthcare, smart services, smart management, grassroots healthcare, smart health, and urban health data space [2] - The solution was launched in early 2025, quickly validated in the market, and scaled up, demonstrating its practical value and providing feedback for continuous iteration [2] Technological Advancements - "Tianyi" AI 2.0 has achieved breakthroughs in three dimensions: data foundation, empowerment platform, and value expansion, reflecting Neusoft Group's deep understanding of the medical business and integration with healthcare systems and human needs [2] - The company emphasizes that the best AI seamlessly integrates into the entire medical process, enhancing convenience for medical staff and improving patient experience, ultimately ensuring equitable and high-quality healthcare for everyone [2]